Eli Lilly & Co. will spend US$5.3 billion to boost production of a key ingredient in its weight-loss and diabetes shots after the treatments’ explosive popularity led to shortages.
Carry Trade Is All the Rage Across Global Bond and FX MarketsBofA’s Hartnett Says Stock Rally Is Moving Closer to Sell SignalPollution Concerns Rise as Water Leaks Into German Nuclear SiteECB’s Nagel Says Likelihood of June Cut Is Winning TractionThames Water Lender to Offload £500 Million of Loans Amid Election LimboRate Cuts Will Trigger Flood of Bond Buying, PGIM SaysInvestors Cast Wider Net For AI Winners After Nvidia DeliversJailed Russian Tycoon Wins UK Ruling to Block $7.
5 Billion PayoutInsurers Are Working to Shore Up the $2 Billion Carbon Offset MarketCrop Index Erases 2024 Loss, Rekindling Food Inflation WorriesLobster and Country Music: Biden, Tech Chiefs Fete Kenya’s RutoGlencore Snubbed in Plan to Showcase Carbon Capture in AustraliaGoldman pushes first Fed rate cut call to September from JulyU.K. urges Canada to ratify its entry into Pacific trade pactU.S.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eli Lilly's GLP-1 demand drives up stock price post-Q1 resultsShares of Eli Lilly (LLY) are soaring in Tuesday's trading session after the company raised its full-year guidance, driven by the surging demand for its...
Read more »
Eli Lilly stock jumps on weight-loss drug sales forecastShares of Eli Lilly (LLY) are moving higher on Tuesday morning as the company reported its first-quarter earnings results, revealing a 26% year-over-year...
Read more »
Eli Lilly reports $2 billion from Mounjaro, Zepbound in Q1 2024Eli Lilly missed on total sales in the first quarter, but its GLP-1 drugs helped boost sales by 26% over those in Q1 2023.
Read more »
US FDA panel to discuss Eli Lilly Alzheimer's drug on June 10Explore stories from Atlantic Canada.
Read more »
Eli Lilly reaches settlement with spa selling Mounjaro, Zepbound knockoffsExplore stories from Atlantic Canada.
Read more »
China Clears Eli Lilly’s Weight-Loss Drug, Only for Diabetes NowChina gave the greenlight to Eli Lilly & Co.’s blockbuster drug tirzepatide for use in treating diabetes, a move that will intensify the drugmaker’s rivalry with Novo Nordisk A/S over weight-loss drugs in the world’s second-largest market.
Read more »